National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Bezlotoxumab (Zinplava®) is indicated for the prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI.

 

NCPE Assessment Process Complete
Rapid review received 11/05/2017
Rapid review completed 14/06/2017
Rapid Review outcome Full pharmacoeconomic evaluation recommended
Full pharmacoeconomic assessment commissioned by HSE 14/06/2017
Current Status Company to not plan to submit

The company do not plan to submit a HTA dossier to the NCPE therefore the cost effectiveness of the technology cannot be proven.